** ASX-listed shares of medical device-maker ResMed RMD.AX fall as much as 7.3% to A$36.02, their lowest level since April 24
** Stock of co, which is involved in treating sleep apnea, COPD and other chronic diseases, marks biggest intraday pct loss since March 12
** RMD is the top pct loser on the ASX 200 benchmark
** Rival Apnimed, which is unlisted, announced positive topline results in first phase 3 clinical trial of AD109, an oral pill for obstructive sleep apnea
** Stock up 0.6% YTD
(Reporting by Sneha Kumar in Bengaluru)
((Sneha.kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。